I sometimes put 2 and 2 together and get 6, but....
That said....
"The Company was approached by another manufacturer which offered to fund the Company’s development of a specialized needle set for a subcutaneous application for rates considerably faster than current drugs. The Company would subsequently be expected to manufacture and market the specialized needle set."
Themn some insider activity lately including the CEO paying $120,000 to exercise options that he's not selling and just holding.
Buyout coming? REPR could be swallowed for a huge premium at a cost that would be nothing to another company.